Lymphoma Clinical Trials in Philadelphia

Showing 421-440 of 701 trials

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

NCT00603668

This study will test different doses of anti-CD74 antibody in patients with NHL and/or CLL.

Gilead Sciences19 participantsStarted Aug 2008

Birmingham, Alabama, United States • Washington D.C., District of Columbia, United States • Orlando, Florida, United States +2 more locations

TERMINATEDPhase 1< 1 mile

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

NCT00054834

The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.

Non-Hodgkins Lymphoma

Gilead Sciences27 participantsStarted Mar 2003

Philadelphia, Pennsylvania, United States • Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

NCT00742027

This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correlate with efficacy or safety were explored.

Classical Hodgkin's Lymphoma

Novartis Pharmaceuticals129 participantsStarted Sep 2008

Duarte, California, United States • Atlanta, Georgia, United States • Augusta, Georgia, United States +43 more locations

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

Other Conditions in Philadelphia